Filing Details

Accession Number:
0001209191-19-061050
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-17 20:02:14
Reporting Period:
2019-12-13
Accepted Time:
2019-12-17 20:02:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
873303 Sarepta Therapeutics Inc. SRPT Pharmaceutical Preparations (2834) 930797222
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1685994 Alexander Cumbo 215 First Street
Suite 415
Cambridge MA 02142
Evp, Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-13 2,727 $13.71 13,888 No 4 M Direct
Common Stock Acquisiton 2019-12-13 3,895 $13.71 17,783 No 4 M Direct
Common Stock Acquisiton 2019-12-13 26,084 $26.24 43,867 No 4 M Direct
Common Stock Disposition 2019-12-13 32,706 $125.50 11,161 No 4 S Direct
Common Stock Disposition 2019-12-13 9,294 $125.50 1,867 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2019-12-13 2,727 $0.00 2,727 $13.71
Common Stock Stock option (right to buy) Disposition 2019-12-13 3,895 $0.00 3,895 $13.71
Common Stock Stock option (right to buy) Disposition 2019-12-13 26,084 $0.00 26,084 $26.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,123 2016-09-09 2026-02-28 No 4 M Direct
0 2017-02-28 2026-02-28 No 4 M Direct
20,881 2014-01-02 2023-01-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,441 Indirect By grantor retained annuity trust
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.